Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Treatment with decitabine resulted in a similar survival and fewer adverse event...
Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML ( Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany )
13 Jun 2022
Lack of access to new cancer medicines in LMICs
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Lack of access to new cancer medicines in LMICs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
11 Jun 2022
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG1...
Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases ( Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA )
10 Jun 2022
Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )
10 Jun 2022
ASCO 2022: Head and neck cancer highlights
Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA
ASCO 2022: Head and neck cancer highlights ( Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA )
10 Jun 2022
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )
9 Jun 2022
Comment: LUMINA results show that women with low levels of the Ki67 biomarker ca...
Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA
Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )
9 Jun 2022
Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
9 Jun 2022
Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A...
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
7 Jun 2022
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can ...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
7 Jun 2022
Biomarker analysis of the NeoALTTO trial provides oncofertility insight for youn...
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2022